Efficiency of Rosuvastatin Versus the Fixed Combination of Ezetimibe/Simvastatin in Outpatients

Efficiency of Rosuvastatin Versus the Fixed Combination of Ezetimibe/Simvastatin to Reduce the Cholesterol Levels in Outpatients in a Realistic Environment. A Retrospective Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01164397

Enrollment

268

Registered

2010-07-16

Start date

2009-04-30

Completion date

2010-12-31

Last updated

2012-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia

Keywords

Hypercholesterolemia, Statins

Brief summary

The aim of this study is to evaluate the effectiveness of Rosuvastatin versus Ezetimibe/Simvastatin in dyslipidemic patients treated for at least 8 weeks.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Dislipidemic population treated with rosuvastatin or ezetimibe/simvastatin for at least for 8 weeks * Who have completed at least 80% of the treatment * To have determinations at least of CT, TG C-LDL and CHDL before starting treatment and after 8 weeks of taking the medicine

Exclusion criteria

* Initiating different therapy lipid lowering to Rosuvastatin or Ezetimibe/Simvastatin

Design outcomes

Primary

Measure	Time frame
The percentage of the patients that achieve the goal proposed for NCEP ATP III (2001 y 2004) will be assessed, to C-LDL in patients treated with Rosuvastatin or Ezetimibe/Simvastatin at least for 8 weeks.	Data will be collected using CRFs after complete at least 15 patients over a 24 week period.

Secondary

Measure	Time frame
The percentage of LDL-C reduction according to baseline levels in patients treated wuth Rosuvastatin or Ezetimibe/Simvastatin for at least 8 weeks.	Data will be collected using CRFs after complete at least 15 patients over a 24 week period.

Countries

Mexico

Outcome results